Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Centocor and Schering-Plough have revised their 1998 distribution agreement for the development, commercialization and distribution of both Remicade, for chronic inflammatory disorders, and golimumab, Centocor's next-generation, human, anti-TNF alpha therapy which is in Phase III trials for the treatment of rheumatoid arthritis.
Subscribe to our email newsletter
Effective upon regulatory approval of golimumab in the EU, the revised agreement will extend the duration of Schering-Plough’s rights to exclusively market Remicade in its current marketing territories outside the US beyond 2014 to match the current duration of its exclusive marketing rights for golimumab product. Schering-Plough’s marketing rights to both products will now extend for 15 years after the first golimumab commercial sale.
In addition, Centocor will receive a progressively increased share of profits on Schering-Plough’s distribution of both products in the Schering-Plough marketing territory between 2010 and 2014, and remaining fixed thereafter for the remainder of the term. The revised agreement will also allow Schering-Plough to independently develop and market golimumab for the Crohn’s disease indication in its territories, with an option for Centocor to participate in the program.
The parties have also agreed to utilize an autoinjector device developed by Centocor affiliate Cilag International in the commercialization of golimumab in their respective territories and have further agreed to share the autoinjector development costs.